Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Bluejay Therapeutics logo — Developing innovative cures for infectious diseases with the...

Bluejay Therapeutics

Developing innovative cures for infectious diseases with the first target indication of chronic HDV infection

Founded 2020 United States United States 11 employees Series C Total: $242.24M Biotechnology, Health Care +1

General Information

Company Name Bluejay Therapeutics
Founded Year 2020
Location United States United States
Employees 11
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series C
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Bluejay Therapeutics. To contact Bluejay Therapeutics, visit bluejaytx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bluejay Therapeutics compare?

A PDF of Bluejay Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bluejay Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Bluejay Therapeutics

Bluejay Therapeutics, founded in 2020 and headquartered in the United States, is making significant strides in the Biotechnology, Health Care, and Pharmaceutical industries. The company is dedicated to developing innovative cures for infectious diseases, with a promising initial focus on the chronic HDV infection.

Under the evocative slogan, "Developing innovative cures for infectious diseases with the first target indication of chronic HDV infection," Bluejay Therapeutics has captured investor interest and confidence. The company recently secured a substantial $182.00M in a Series C investment round on 09 May 2024. Notable investors in this round include Novo Holdings, HBM Healthcare Investments, RA Capital Management, RiverVest, T. Rowe Price, Wellington Management, Octagon Capital Advisors, Unicorn Capital Partners, Frazier Life Sciences, and Arkin Bio Ventures.

With a clear mission and robust financial backing, Bluejay Therapeutics stands as a compelling option for potential investors looking to make impactful investments in the fight against infectious diseases.

Business keywords: Biopharmaceutical, Infectious Diseases, Chronic HDV Infection, Hepatitis B, Functional Cure, Monoclonal Antibodies, IgG1 Anti-HBs, HBsAg Inhibitors, Small Molecule Inhibitors, Adaptive Immunity Restoration, Medical Innovation, Healthcare Solutions, Immunotherapy, Therapeutic Development, Biotechnology Startup

Services & Products

Development of therapeutics for liver diseases
Acquisition and integration of biotech companies
Research and development in chronic hepatitis delta virus treatment

Target Customers

Patients with liver diseases Healthcare providers Biotechnology investors Medical professionals specializing in rare diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $182.00M 10
Novo Holdings HBM Healthcare Investments RA Capital Management
Novo Holdings, HBM Healthcare Investments +8
09 May 2024
Series B $41.00M -
16 Aug 2022
Venture Round $19.24M -
17 Jun 2021

Bluejay Therapeutics Alternatives & Competitors

View All Alternatives
Bluejay Therapeutics vs
InflaRx
InflaRx Germany

Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory disea...

Post-IPO Equity
46 employees
Health Care, Health and Wellness
Bluejay Therapeutics vs
Evommune
Evommune United States

Developing innovative therapies that target key drivers of chronic inflammatory diseases.

69 employees
Biotechnology, Health Care
Bluejay Therapeutics vs
Dyne Therapeutics
Dyne Therapeutics United States

Advancing life-transforming therapies for serious muscle diseases

Post-IPO Equity
292 employees
Biotechnology, Health Care
View all alternatives

FAQ About Bluejay Therapeutics

Developing innovative cures for infectious diseases with the first target indication of chronic HDV infection
Bluejay Therapeutics was founded in 2020.
Bluejay Therapeutics is headquartered in United States.
Bluejay Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Infectious Diseases, Chronic HDV Infection and Hepatitis B. Its customers include Patients with liver diseases, Healthcare providers and Biotechnology investors.
Bluejay Therapeutics has a B2B business model. Its revenue comes from Licensing and Product Sales.
Bluejay Therapeutics has approximately 11 employees.
Bluejay Therapeutics has completed 3 funding rounds, raising a total of $242.24M. The latest funding stage is Series C.
Bluejay Therapeutics offers: Development of therapeutics for liver diseases, Acquisition and integration of biotech companies, Research and development in chronic hepatitis delta virus treatment.
Top alternatives and competitors to Bluejay Therapeutics include InflaRx, Evommune, Dyne Therapeutics, Nuvamid, Alltrna. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bluejay Therapeutics and InflaRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bluejay Therapeutics, https://bouncewatch.com/company/bluejay-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout